Mesa Laboratories (NASDAQ:MLAB) Shares Up 4.7%

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) were up 4.7% during trading on Wednesday . The stock traded as high as $104.91 and last traded at $104.11. Approximately 14,753 shares changed hands during trading, a decline of 71% from the average daily volume of 51,213 shares. The stock had previously closed at $99.40.

Analyst Upgrades and Downgrades

Separately, Evercore ISI raised shares of Mesa Laboratories from an "in-line" rating to an "outperform" rating and upped their price target for the stock from $100.00 to $125.00 in a research report on Thursday, January 4th.

Mesa Laboratories Stock Up 0.4 %

The firm's 50-day moving average price is $102.35 and its 200-day moving average price is $100.17. The company has a market cap of $537.92 million, a price-to-earnings ratio of 587.09 and a beta of 0.83. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.68 and a quick ratio of 1.86.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last released its quarterly earnings data on Monday, February 5th. The medical instruments supplier reported $1.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.47 by ($0.01). Mesa Laboratories had a return on equity of 7.41% and a net margin of 0.45%. The business had revenue of $53.47 million during the quarter, compared to analyst estimates of $54.90 million. Sell-side analysts forecast that Mesa Laboratories, Inc. will post 6.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mesa Laboratories

Several large investors have recently made changes to their positions in MLAB. Vanguard Group Inc. grew its holdings in Mesa Laboratories by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 370,278 shares of the medical instruments supplier's stock valued at $38,794,000 after purchasing an additional 7,274 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Mesa Laboratories by 5.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,698 shares of the medical instruments supplier's stock valued at $283,000 after purchasing an additional 136 shares in the last quarter. Barclays PLC grew its holdings in Mesa Laboratories by 359.8% during the 4th quarter. Barclays PLC now owns 11,664 shares of the medical instruments supplier's stock valued at $1,222,000 after purchasing an additional 9,127 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in Mesa Laboratories by 0.9% during the 4th quarter. Nuveen Asset Management LLC now owns 13,106 shares of the medical instruments supplier's stock valued at $1,373,000 after purchasing an additional 120 shares in the last quarter. Finally, Public Sector Pension Investment Board grew its holdings in Mesa Laboratories by 68.2% during the 4th quarter. Public Sector Pension Investment Board now owns 10,631 shares of the medical instruments supplier's stock valued at $1,114,000 after purchasing an additional 4,309 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company's stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.